Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
Haleon, maker of Advil and TUMS, reported a 24% sales lift in U.S. stores by targeting consumers on GLP-1 weight-loss drugs. The company partners with CVS Pharmacy, Walmart, and Target to place products in GLP-1-specific sections and regular aisles. About 11% of Americans use GLP-1 drugs, per Gallup. CVS expanded its product assortment to help manage side effects.
How this was made
The 30-second read
Why it matters
Haleon's strategy targets this emerging niche, potentially increasing its U.S. OTC sales and market share.
Market read
First report of a measurable sales boost from a new retail placement strategy for a major consumer‑health firm.
What to watch
Impact depends on CVS shelf‑space allocation and consumer adoption of GLP‑1 drugs, which could vary.
Background
GLP‑1 weight‑loss drugs like Wegovy and Zepbound are gaining market share, creating demand for OTC products that address their side‑effects.
Ticker impact
Haleon disclosed a 24% average sales lift per store in Q1 by placing OTC products in GLP-1 drug sections at CVS.
Potential modest upside for HLN as investors price in higher U.S. sales growth.
First‑time disclosure of a measurable sales lift; scale is limited to a niche shelf but could be replicated across other retailers.
Market effects
Highlights growing demand for OTC products that mitigate GLP‑1 side effects, benefiting consumer‑health retailers.
U.S. OTC market may see incremental growth as GLP‑1 usage expands.
Signals a new retail channel for weight‑loss drug adjuncts worldwide.
Counterpoint
The sales lift may be temporary if GLP‑1 prescriptions plateau or if competitors launch similar shelf‑space deals.
Key entities
- CompanyHaleon
Consumer health company behind Advil, TUMS, Biotène.
- RetailerCVS Pharmacy
U.S. pharmacy chain partnering with Haleon on GLP‑1 shelf space.
